Atopic dermatitis (AD) is a multifactorial, predisposed, chronic inflammatory and pruritic skin disease often as sociated with allergic asthma (AA) and/or rhinoconjunc tivitis (AR) (1) . Treatment of patients with AD with the humanized antibody omalizumab (Xolair ® , Novartis, Nuremberg, Germany), which is also effective in AA, AR, urticaria and mastocytosis (2) , has resulted in either improvement or treatment failure (3) (4) (5) . The underlying mechanism in AD patients with high serum immunoglo bulin E (IgE) levels remains unclear (3, 5) . We report here a case of longterm treatment of AD with omalizumab.
CASE REPORT
A 53-year-old man presented in June 2005 with chronic and relapsing severe exacerbated AD of the extremities, face, chest and upper back. His lower arms and legs displayed highly pru ritic erythematous lichenoid papules in a linear orientation that had been directly induced by scratching (Fig. 1a) . His AD had begun in childhood and was further exacerbated at 35 years of age due to the presence of continuous lymphadenopathy and frequent bacterial and viral skin superinfections. He also had early onset allergic rhinoconjunctivitis and severe asthma with forced expiratory volume in one second 25% and lung emphy sema characterized by α-1 antitrypsin deficiency. Skin-prick tests and radioallergosorbent testing-confirmed type-I sensitivity against pollen (birch, hazel, alder, mugwort and rye), dust mites, epithelia (from horse, cat and dog), Pityrosporom, latex, milk and codfish protein. Specific IgE to relevant allergens represented < 1% of the total IgE. AD flared up when exposed to seasonal aeroallergens. Skin-patch tests revealed contact allergies against cocamidopropyl betaine and sorbitan sesquioleate. Ultraviolet (UV) provocation revealed UVA and UVB hypersensitivity. IgE serum levels were persistently elevated (> 15,000 kU/l). His family history was positive for asthma but negative for AD. The patient continuously took various anti-histamines, fluticasone/ salmeterol and theophylline and applied topical steroids daily.
Years of systemic therapy with prednisolone or cyclosporine had not sustainably improved the patient's condition or prevent flare-ups. Microbiological analysis confirmed repeated superin fections with Staphylococcus aureus and/or herpes simplex virus (HSV)-1, which were treated with local antiseptics and/or systemic antibiotics/ antivirals. In 2005, dermatohistopathology excluded lichen planus, lichen amyloidosis, other deposition dermatoses, plasmacy toma, IgE-lymphoma, mastocytosis and cutaneous T-cell lymphoma (CTCL). The same analysis re-confirmed AD ( Fig. 1b  and 1c ). Sonography revealed inflamma tory, reactive lymph nodes (dermatopathic lymphadenopathy). Increased serum levels of tumour necrosis factor (TNF)-α and a CD4/CD8 ratio of 4 were detected. Serum protein electrophoresis and quantitative measurements excluded monoclonal gam mopathy. Due to insufficient efficacy, cyclospori ne treatment was tapered, and extracorpo real photopheresis (ExP) was employed biweekly. After 4 cycles of ExP, the condi tion of the patient's skin improved signifi cantly. ExP intervals were prolonged for 1 week until cycle 10 and again for 1 week until cycle 19. SCORAD (SCORing Atopic Dermatitis) dropped from 80 to 40 within 8 months (10 ExP-cycles), but no further improvement occurred thereafter. The clinical course and paraclinical parameters are illustrated schematically in Fig. 2 treatment, and was further increased to 375 mg/s.c. biweekly 5 months later. This resulted in long-term stabilization and finally complete remission with clearance of the marked lichenoid papu les from the extremities (Fig. 1) . From January to October 2010, the dosage was reduced to 300 mg s.c. every 2 weeks, followed by a further reduction to 300 mg every 4 weeks in October 2010.
The phase of combined ExP and omalizumab treatment was well tolerated. The flare-up periods induced by aeroallergens disappeared. The last herpes virus superinfection occurred in November 2006. Topical steroid consumption decreased by 90%, so class III steroids were replaced with class II steroids and further substituted with pimecrolimus. The dosage of systemic antihistamines was also reduced 3 to 4fold.
Serum tryptase levels normalized (from 33.5 to 13.2 µg/l) during treatment (Fig. 2) . The levels of eosinophilic cationic protein (ECP, 65.7 µg/l) and blood eosinophils (19%) dropped during ExP, relapsed at the end of ExP and normalized again during anti-IgE therapy (ECP 3.49 µg/l; eosinophils 3%). IgEserum levels rose after the initiation of omalizumab treatment (due to formation of omalizumab/IgE complexes, which have a slower elimination rate than free IgE) and finally reached a maximum at the end of 2007 (22,357 kU/l). This trend was then dramatically reversed; in November 2010, the lowest IgE-level (10,112 kU/l) in over 15 years was recorded (Fig. 2) .
In our patient, ExP was employed as a third-line therapy after severe exacerbations during classic immunosuppressive AD treat ment with corticosteroids and/or cyclosporine. SCORAD levels dropped to approximately 50% of initial values within 10 cycles of ExP without further improvement. This case report confirms 2 open trials with 42 ExP-treated AD patients. Only 3 out of 18 AD patients who required ExP treatment >20 weeks showed complete remission. ExP non-responders displayed higher levels of IgE (>10,000 kU/l) (literature reviewed in Table  SI available from available 
DISCUSSION
Fifty-four out of 75 omalizumab-treated AD patients reported in the literature showed a positive clinical response, but only 10 of them achieved complete remis sion. Among 10 AD patients who were comparable to our case regarding severity and IgE level, 5 benefited from omalizumab therapy. They were treated with 150-450 mg omalizumab biweekly for up to 20 weeks. None of them achieved complete remission. Our patient did not respond to lowdose antiIgE treatment and failed to display a significant reduction in SCORAD for almost one year. Omalizumab at 300 and 450 mg in a biweekly alteration regimen led to a continuous and longlasting clinical improvement with a reduced need for systemic or topical medication over the next 5 years. Paraclinical parameters also declined, in contrast to previously reported findings.
The mechanism by which omalizumab modulates skin inflammation remains unclear. In patients with allergic rhinoconjunctivitis and/or asthma, antiIgE treatment is most effective if allergen-specific IgE levels are < 1% of the total IgE level that is treated with recommended doses (6) . In AD, clinical improvement does not seem to completely depend on total IgE levels (7, 8) . In our case, ExP, which is known to enhance the regulatory T-lymphocyte network (9) , could have suppressed the immune dysregulation. Furthermore, the interference of omalizumab with the IgE receptor systems and/or the immunocomplex-degrading network could have further downregulated the AD immune response including IgEsecreting plasma cells (10) . The normalization of serum tryptase indicates the influence of omalizumab on the basophil/mast cell system (2). Furthermore, allergen-specific IgE levels could have been sufficiently inactivated by high doses of anti-IgE treatment.
In conclusion, the combination of ExP and omalizumab may be an interesting option for the treatment of severe, recalcitrant AD in patients with severe asthma, even in those with high levels of serum IgE. Long-term anti-IgE treatment was safe in our patient and may be considered as part of a multifactorial therapeutic concept.
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